Aetna CEO interested in more personalized care

John Gregory | November 09, 2017 | Health Exec | Precision Medicine

Aetna CEO Mark Bertolini said the future of his company will be tailored towards a more individualized version of healthcare, calling his interest in an Apple-style business model for the industry “a real deal.” One deal he wouldn’t talk about, however, was the rumored purchase of Aetna by CVS.

Speaking at a technology conference in California, Bertolini said his company is heading towards personalized healthcare and understanding what patients want on an individual basis.

“I think we need to keep people away from the health care system,” he said, according to the Hartford Courant. “We should have an attitude that when somebody has to go to an emergency room or they have to go in the hospital or they need to see a specialist, we have failed them in some way.”

Bertolini touched on a variety of subjects, from the need to reduce the growth in healthcare prices and to Aetna’s move of its corporate headquarters fron Hartford to New York, saying employees were enthusiastic about relocating. But when it came to the CVS deal, his lips were sealed.

“Of course I’m not allowed to comment nor will I comment on market speculation,” Bertolini said.

Read the full article at the link below:

With Or Without CVS, Bertolini Describes Aetna's Future

John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Cardiovascular Business

Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more.

Cardiovascular Business

Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business

FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country.

Aetna CEO interested in more personalized care

Related Content

Around the web